Skip to content

Savara SVRA Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
$10.7M
TRV
Trevi Therapeutics, Inc.TRVI
$2.54M

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+134%
Enterprise value$1.19B+127%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: Savara’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's proceeds from warrant exercises?
Savara (SVRA) reported proceeds from warrant exercises of $500 in Q4 2025.
How has Savara's proceeds from warrant exercises changed year-over-year?
Savara's proceeds from warrant exercises decreased by 71.4% year-over-year, from $1.75K to $500.
What does proceeds from warrant exercises mean?
This represents the cash proceeds received by the company when holders of warrants exercise their right to purchase common stock at a predetermined price. This serves as a source of capital that typically occurs when the company's stock price exceeds the warrant strike price. It provides insight into the potential dilution of existing shareholders and the conversion of derivative instruments into equity.